20/20 Biolabs, Inc. AIDX
Precision Instruments · data as of November 13, 2026
20/20 Biolabs, Inc. (AIDX) is a healthcare company listed in the US with a market value of about $3M. In the twelve months to June 30, 2026 it had revenue of $2M and net income of -$6M, a net margin of -285.0%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -278%.
About 20/20 Biolabs
20/20 Biolabs is listed in the US and classified in precision instruments. It was profitable in 0 of the last 2 years in our data. It spends 29% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 2 years
| Fiscal year | TTM | 2025 | 2024 |
|---|---|---|---|
| Revenue | $2M | $2M | $2M |
| Net income | -$6M | -$4M | -$6M |
| Free cash flow | -$3M | -$2M | -$3M |
| EPS (diluted) | $-0.97 | $-0.76 | $-1.16 |
| Net margin | -285.0% | -182.8% | -316.8% |
| ROIC | — | -365.4% | -191.3% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does 20/20 Biolabs pay a dividend?
Not currently.
Is 20/20 Biolabs a good stock to buy?
We do not give buy or sell advice. 20/20 Biolabs scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.